Business Context and Reporting Period
This Form 8-K is filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on November 9, 2017. The filing serves to announce company highlights and financial results for the third quarter ended September 30, 2017. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the filing text itself.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. It only indicates that such results were announced in the referenced press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information disclosed under Item 2.02, including the press release, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it shall not be incorporated by reference into any registration statement unless expressly set forth. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Verify the correct registrant name is Trovagene, Inc., as the input metadata incorrectly listed Cardiff Oncology, Inc.
- Review Exhibit 99.1 (the press release) to obtain actual financial figures for the quarter ended September 30, 2017.
- Confirm that the financial data in the press release is not incorporated by reference into other SEC filings unless explicitly stated.
- Check for subsequent filings to see if Trovagene, Inc. has undergone any name changes or mergers since 2017.